Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia

Blood

Volumn 99, Issue 6, 2002, Pages 2146-2153

  LaBelle, James L ^a,b   Hanke, Carrie A ^a,b   Blazar, Bruce R ^a,b   Truitt, Robert L ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; FEMALE; IMMUNITY; IMMUNOGENICITY; MOUSE; MYELOID LEUKEMIA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR GROWTH;

EID: 0037085792     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.6.2146     Document Type: Article

References (53)

1. Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy
2. T cell antigen receptor signal transduction pathways
3. The role of cell division in the induction of clonal anergy
4. Induction of antigen-specific T cells by allogeneic CD80 transfected human carcinoma cells
5. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
6. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors
7. + T cells by B7-transfected melanoma cells
8. Manipulation of costimulatory signals to enhance antitumor T-cell responses
9. Enhancement of antitumor immunity by CTLA-4 blockade
10. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity: Further evidence that B7-1 and B7-2 are functionally distinct
11. B7-1 but not B7-2 efficiently co-stimulates CD8+ T lymphocytes in the P815 tumor system in vitro
12. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor
13. Vaccination with mouse mammary adenocarcinoma cells coexpressing B7-1 (CD80) and B7-2 (CD86) discloses the dominant effect of B7-1 in the induction of antitumor immunity
14. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic antitumor immunity against different mouse tumors
15. Immunogene therapy against mouse leukemia using B7 molecules
16. + T-cell line with potent in vivo graft-versus-leukemia properties
17. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
18. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
19. Myeloid leukemia C1498 as a screen for cancer chemotherapeutic agents
20. A survey of transplantable and transmissible animal tumors
21. + T-cell immune response to murine myeloid leukemia
22. A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo
23. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors
24. A reassessment of the role of B7-1 expression in tumor rejection
25. + T cells
26. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4
27. Lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous
28. CTLA-4 ligation blocks CD28-dependent T cell activation
29. + T cells become nonresponsive (anergic) following activation in the presence of costimulation
30. + T cell-and IL-2-dependent mechanism
31. B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism
32. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid cells
33. B7-2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding
34. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor
35. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma
36. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity
37. + T cells in vitro
38. Active antitumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model
39. B7-1, IFNγ and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma
40. + T cell-dependent mechanism
41. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
42. The role of p21 ras in CD28 signal transduction: Triggering of CD28 with antibodies, but not the ligand B7-1, activates p21ras
43. CD80 and CD86 are not equivalent in their ability to induce the tyrosine phosphorylation of CD28
44. Differential down-regulation of CD28 by B7-1 and B7-2 engagement
45. Both extracellular immunologlobulin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28
46. Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2)
47. Differential recognition by CD28 of its cognate counter receptors CD80 (B7-1) and B70 (B7-2): Analysis by site directed mutagenesis
48. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics
49. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
50. CD2 and the nature of protein interactions mediating cell-cell recognition
51. The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function
52. CD152 ligation by CD80 on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation